Resultados de búsqueda undefined

Anónimo {{'2022-03-11T15:41:00.000Z' | moment 'DD/MM/YY HH:mm'}} /#/ 258788

>>258718
>Figure 1. Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Age at Onset of Myocarditis
Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Age at Onset of Myocarditis
The reports to the Vaccine Adverse Event Reporting System met the case definition of myocarditis (reported cases). Among individuals older than 40 years of age, there were no more than 8 reports of myocarditis for any individual age after receiving either vaccine. For the BNT162b2 vaccine, there were 114 246 837 first vaccination doses and 95 532 396 second vaccination doses; and for the mRNA-1273 vaccine, there were 78 158 611 and 66 163 001, respectively. The y-axis range differs between panels A and B.

Figure 2. Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Time From Vaccination to Symptom Onset
Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Time From Vaccination to Symptom Onset
The reports to the Vaccine Adverse Event Reporting System met the case definition of myocarditis (reported cases). Among recipients of either vaccine, there were only 13 reports or less of myocarditis beyond 10 days for any individual time from vaccination to symptom onset. The y-axis range differs between panels A and B.

A, For the BNT162b2 vaccine, there were 138 reported cases of myocarditis with known date for symptom onset and dose after 114 246 837 first vaccination doses and 888 reported cases after 95 532 396 second vaccination doses.

B, For the mRNA-1273 vaccine, there were 116 reported cases of myocarditis with known date for symptom onset and dose after 78 158 611 first vaccination doses and 311 reported cases after 66 163 001 second vaccination doses.

Table 1. Characteristics of Reports to VAERS After mRNA-Based COVID-19 Vaccination That Met the CDC’s Case Definition for Myocarditis Between December 14, 2020, and August 31, 2021
Characteristics of Reports to VAERS After mRNA-Based COVID-19 Vaccination That Met the CDC’s Case Definition for Myocarditis Between December 14, 2020, and August 31, 2021
Table 2. Reports to VAERS After mRNA-Based COVID-19 Vaccination That Met the CDC’s Case Definition for Myocarditis Within a 7-Day Risk Interval per Million Doses of Vaccine Administered
Reports to VAERS After mRNA-Based COVID-19 Vaccination That Met the CDC’s Case Definition for Myocarditis Within a 7-Day Risk Interval per Million Doses of Vaccine Administered
Table 3. Symptoms, Treatment, and Outcomes in 826 Patients Younger Than 30 Years of Age With Myocarditis
Symptoms, Treatment, and Outcomes in 826 Patients Younger Than 30 Years of Age With Myocarditis and Pericarditis After Vaccination for COVID-19
Research LetterSeptember 28, 2021
This study investigates the incidence of myocarditis and pericarditis emergency department or inpatient hospital encounters before COVID-19 vaccine availability (January 2019–January 2021) and during a COVID-19 vaccination period (February-May 2021) in a large US health care system.
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Brief ReportOctober 1, 2021
This case series describes myocarditis presenting after COVID-19 vaccination within the Military Health System.
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination
Brief ReportOctober 1, 2021
This study describes 4 patients who presented with acute myocarditis after mRNA COVID-19 vaccination.
Association of Myocarditis With BNT162b2 Vaccination in Children
Brief ReportDecember 1, 2021
This case series reviews comprehensive cardiac imaging in children with myocarditis after COVID-19 vaccine.
See More About
Public Health Vaccination Cardiology Coronavirus (COVID-19)
Select Your Interests
Others Also Liked
Myocarditis after vaccination against covid-19
Walid F Gellad et al., The BMJ, 2021
Covid-19: Study that claimed boys are at increased risk of myocarditis after vaccination is deeply flawed, say critics
Clara Munro, The BMJ, 2021
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
Anders Husby et al., BMJ's Coronavirus (covid-19) Hub, 2021
Powered by
Comment
2 Comments for this article
February 1, 2022
Publication Delay
Peter Yim, PhD | Virtual Scalpel, Inc.
The study reports increases in the risk of myocarditis from mRNA vaccination based on reports to VAERS and on pre-COVID-19 reference data. The reports were submitted to VAERS in the December 2020 to August 2021 time frame.

The publication is late. It comes nearly eight months since the CDC identified the potential myocarditis risk and nearly five months after the VAERS reports were submitted. Why the delay in publication?
CONFLICT OF INTEREST: Founder and Chief Scientific Officer, Virtual Scalpel, Inc
February 10, 2022
Sex Differences in Risk and Activity
David Henson, BSN, RN. M.Sc | Nebraska Medical Center (Alum)
I was curious as to the physical activity levels of these study participants. Is there any suggestion of active subjects in this study playing intense sports, or exercise, immediately following the 2nd vaccination? Should a guideline be presented for athletes to rest for a period of time, to allow normal return of immune response? I am also a college soccer coach so I have extreme interest in this topic for my players' safety.
CONFLICT OF INTEREST: None Reported
This Issue
Views 696,731 Citations 3
9033
Comments 2
PDF

CME & MOC
Original Investigation
January 25, 2022
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
Matthew E. Oster, MD, MPH1,2,3; David K. Shay, MD, MPH1; John R. Su, MD, PhD, MPH1; et alJulianne Gee, MPH1; C. Buddy Creech, MD, MPH4; Karen R. Broder, MD1; Kathryn Edwards, MD4; Jonathan H. Soslow, MD, MSCI4; Jeffrey M. Dendy, MD4; Elizabeth Schlaudecker, MD, MPH5; Sean M. Lang, MD5; Elizabeth D. Barnett, MD6; Frederick L. Ruberg, MD6; Michael J. Smith, MD, MSCE7; M. Jay Campbell, MD, MHA7; Renato D. Lopes, MD, PhD, MHS7; Laurence S. Sperling, MD1,2; Jane A. Baumblatt, MD8; Deborah L. Thompson, MD, MSPH8; Paige L. Marquez, MSPH1; Penelope Strid, MPH1; Jared Woo, MPH1; River Pugsley, PhD, MPH1; Sarah Reagan-Steiner, MD, MPH1; Frank DeStefano, MD, MPH1; Tom T. Shimabukuro, MD, MPH, MBA1
Author Affiliations Article Information
JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110
related articles iconRelated
Articles
Key Points
Question What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US?

Findings In this descriptive study of 1626 cases of myocarditis in a national passive reporting system, the crude reporting rates within 7 days after vaccination exceeded the expected rates across multiple age and sex strata. The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively)
En resumidas cuentas,la tasa de muestreo es altisima y los casos son muy bajos

Resultados de la búsqueda: